Dutasteride for biopsy-negative benign prostate hyperplasia - effects on cancer detection and aging male symptoms

Dutasteride for biopsy-negative benign prostate hyperplasia - effects on cancer detection and aging male symptoms - Dutasteride for biopsy-negative benign prostate hyperplasia - effects on cancer detection and aging male symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005288

Enrollment

Registered

2011-03-22

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biopsy-negative benign prostate hyperplasia

Interventions

dutasteride 0.5mg

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. age >=40 2. Written informed consent 3. serum PSA levels >=4.0 4. Patients without prostate cancer 5. Patients with benign prostatic hyperplasia

Exclusion criteria

Exclusion criteria: 1) patients with prostate cancer 2) patients with previous operation on prostate 3) Subjects taking any anti-androgen drugs 4) patients with prostatitis 5) Subjects with active urinary infection 6) Subjects with urethral catheter 7) Subjects with irritation to Eviprostat 8) Severe renal dysfunction 9) Severe liver dysfunction 10) Other ineligible subjects

Design outcomes

Primary

Measure	Time frame
Cancer detection by prostatic biopsy	—

Countries

Japan

Contacts

Public ContactHiroshi Fukuhara

University of Tokyo Hospital Department of Uology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026